XNAS
ONCY
Market cap54mUSD
Oct 08, Last price
0.54USD
1D
-8.63%
1Q
-38.65%
IPO
-91.08%
Name
Oncolytics Biotech Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
18.90%
Rev. gr., 5y
%
Revenues
0
Net income
-29m
L-9.31%
CFO
-20m
L-25.42%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Key people
Chairman of the Board · since 2025
Jared Kelly
Chief Executive Officer, Director · since 2025
Kirk Look
Chief Financial Officer · since 2021
Andrew Guttadauro
Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc. · since 2017
John McAdory
Executive Vice President - Strategy and Operations · since 2026
Allison Hagerman
Vice President - Product Development · since 2010
Amy Levin
Vice President - Clinical Operations · since 2023
Yujun Wu
Vice President, Head - Biostatistics · since 2026
Thomas Heineman
Chief Medical Officer of Oncolytics Biotech (U.S.) · since 2021
Patricia Andrews
Director · since 2024
Deborah Brown
Independent Director · since 2017
Angela Holtham
Independent Director · since 2014
Independent Director · since 2022
Independent Director · since 2022
Independent Director · since 2015
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||